Compare Invesco Solar ETF (TAN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Solar ETF vs TransMedics Group Inc — how do they compare? Invesco Solar ETF trades at $52.39, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Invesco Solar ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TAN | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $73.95 | $150.42 |
52-Week Low | $36.62 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAN trades at $52.41, up 1.06% in the last session, amid a bearish technical signal with selling pressure outweighing buys 11 to 4. Recent news highlights solar sector volatility and policy impacts, including new polysilicon tariffs under the Trump administration that may reshape U.S. solar manufacturing dynamics. The ETF's high beta of 1.41 indicates elevated sensitivity to market swings compared to broader energy funds.
Outlook is mixed: tariffs could boost U.S.-focused solar stocks but face headwinds from permit delays and weak residential demand. Risks include regulatory uncertainty and competition from nuclear energy. Analyst sentiment is cautious, with downgrades citing valuation and technical deterioration, though long-term growth drivers like AI energy demand persist.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
